German-based Boehringer Ingelheim Pharmaceuticals Inc. agreed to pay $13.5 million to settle allegations by New York, New Jersey, and other U.S. states that it illegally promoted off-label uses for four of its drugs.
The Dec. 20 settlement, joined by all 50 states and the District of Columbia, covers marketing of Micardis, Aggrenox, Atrovent, and Combivent. A coalition of state attorneys general alleged that the company used deceptive and misleading practices to persuade doctors to prescribe the blood system and respiratory drugs for conditions not specifically approved by the Food and Drug Administration.
The action in all 50 states followed ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.